Janus Henderson Group
ANIP icon

Janus Henderson Group’s ANI Pharmaceuticals ANIP Stock Holding History

Janus Henderson Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.42M Buy
109,552
+101,772
+1,308% +$7.94M ﹤0.01% 813
2025
Q4 		$614K Sell
7,780
-78,816
-91% -$6.82M ﹤0.01% 1923
2025
Q3 		$7.93M Buy
86,596
+80,186
+1,251% +$6.54M ﹤0.01% 797
2025
Q2 		$418K Sell
6,410
-3,100
-33% -$202K ﹤0.01% 2031
2025
Q1 		$642K Hold
9,510
– – ﹤0.01% 1826
2024
Q4 		$526K Hold
9,510
– – ﹤0.01% 2007
2024
Q3 		$568K Buy
9,510
+4,333
+84% +$264K ﹤0.01% 1974
2024
Q2 		$329K Sell
5,177
-84
-2% -$5.45K ﹤0.01% 2166
2024
Q1 		$364K Buy
5,261
+3
+0.1% +$181 ﹤0.01% 2155
2023
Q4 		$290K Sell
5,258
-11
-0.2% -$606 ﹤0.01% 2252
2023
Q3 		$306K Buy
5,269
+15
+0.3% +$866 ﹤0.01% 2174
2023
Q2 		$283K Sell
5,254
-8
-0.2% -$355 ﹤0.01% 2280
2023
Q1 		$209K Buy
+5,262
New +$222K ﹤0.01% 2474

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Janus Henderson Group's ANIP Position: Q1 2026 in Review

Janus Henderson Group increased its ANI Pharmaceuticals (ANIP) stake by 1,308% in Q1 2026, buying an estimated $7.94M and bringing the position to 109,552 shares worth $8.42M. The position accounts for ﹤0.01% of the portfolio, ranked #813.

Janus Henderson Group first reported a position in ANIP in Q1 2023 and has held it in 13 quarters since. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Janus Henderson Group held 109,552 shares of ANI Pharmaceuticals worth $8.42M as of Q1 2026.
  • Janus Henderson Group bought 101,772 ANI Pharmaceuticals shares in Q1 2026, an estimated $7.94M.
  • ANI Pharmaceuticals made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #813 holding.
  • Janus Henderson Group first reported a position in ANI Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.